German-based firm Biotronik’s US division has commercially launched its MR conditional quadripolar (QP) cardiac resynchronisation therapy pacemaker (CRT-P), Edora HF-T QP, following approval from the US Food and Drug Administration (FDA).

Featuring MRI AutoDetect technology, 15cc volume, and longevity of approximately ten years, Edora HF-T QP is intended to minimise device replacement frequency for heart failure patients.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The MRI AutoDetect technology has been developed to enhance patient safety by decreasing the time in which the device is in MRI mode.

Once activated by a clinician, the technology automatically identifies an MRI field and changes the device programming to MRI mode.

Biotronik president Marlou Janssen said: “With the launch of Edora HF-T QP, Biotronik offers a full suite of ProMRI products, ensuring physicians can always choose MRI conditional devices for their patients.

"Our devices are the only FDA-approved CRM solutions that provide automatic detection of an MRI environment, physiologic rate adaptation, and automatic daily remote monitoring."

“Our devices are the only FDA-approved CRM solutions that provide automatic detection of an MRI environment, physiologic rate adaptation, and automatic daily remote monitoring.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The pacemaker also includes closed loop stimulation (CLS) and Biotronik Home Monitoring, which is a cardiac device remote monitoring system that comes with automatic, daily transmission verification.

The system features a summary of nine long-term heart failure statistics called Heart Failure Monitor that, in combination with daily updates, enables continuous monitoring and assessment of heart failure status.

According to previous studies, the system is linked to 50% decrease in mortality by heart failure and 36% decrease in hospitalisation for worsening heart failure.

Image: Biotronik Edora 8 HF-T QP. Photo: courtesy of Biotronik.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact